Anticoagulant Reversal Drugs Industry
The global anticoagulant reversal drugs market expected to grow at compound annual growth rate (CAGR) of 15.3% during the forecast period from 2018 to 2026.
Reversing the effects of anticoagulants including novel oral anticoagulants (NOACs), Vitamin K antagonist and others is a major concern in clinical practice especially during life-threatening bleeding episodes and emergency surgery. Approvals of NOACs in last decade has increased the usage of these factor Xa inhibitors in preventing and treating various medical conditions such as stroke, pulmonary embolism, atrial fibrillation, and deep vein thrombosis (DVT). However, this growth in anticoagulants usage has led to the rise in the incidence of hospitals admissions and death due to increased bleeding due to anticoagulation. According to Centers for Disease Control and Prevention (CDC), in the year 2016, approximately 117,000 people were hospitalized in U.S. alone and close to 2,000 deaths per month attributable to anticoagulation or factor Xa inhibitor related bleeding. These factors have led to furious research and development of anticoagulant reversal agents. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) has granted special status and accelerated approvals for development and swift market entry of certain anticoagulant antidotes.
Browse the full report at https://www.credenceresearch.com/report/anticoagulant-reversal-drugs-market
The global anticoagulant reversal drugs market is poised to grow during the forecast period owing to approval of blockbuster drugs in the recent years and strong pipeline driving the market. The U.S. Food and Drug Administration has designated Andexxa (the most recent approved drug for factor Xa inhibitors) as orphan drug and tagged under accelerated approval process. European Medicines Agency is also positive to grant approval for andexanet alfa, with Committee for Medicinal Products for Human Use (CMPH) reviewing the application. Idarucizumab, approved in 2015 for antidote for dabigatran during atrial fibrillation, is currently under clinical trials for multiple conditions such as hemorrhage and stroke. Thus strong pipeline and governmental initiatives will drive the market for anticoagulant reversal drugs market. Drugs type such as prothrombin complex concentrates, Vitamin K, desmopressin which were earlier preferred for contain emergency situation will demonstrate sluggish growth due to launch of novel drugs with better efficacy and quicker effect. However, high prices of patented drugs would act as a growth barrier in emerging economies.
In terms of geography, North America held the largest share in the global anticoagulant reversal drugs market owing to increased approvals and increasing research and development by major pharmaceutical companies in the region. Europe also a held a significant share in the global market attributable to product approvals. Growing incidence of uncontrollable bleeding episodes and usage of anticoagulants will further drive the market in the North America and Europe. U.S. emerged as the largest country level market due to efficient reimbursement scenario of for drugs, high cost of the recently approved drugs and accelerated drug approval initiative by U.S. Food and Drug Administration (FDA) to drive the market. Asia Pacific is set to grow at fastest rate during the forecast period, driven by rising patient population for diseases such as atrial fibrillation, strokes and other cardiopulmonary diseases. Ongoing trials in the region will further stimulate the market growth in the region. The key players currently engaged in anticoagulant reversal drugs market include Boehringer Ingelheim GmbH, Fresenius Kabi AG, Bausch Health Companies, Inc., CSL Behring Limited, Octapharma AG, Portola Pharmaceuticals, Inc., Perosphere Pharmaceuticals, Inc. and Ferring Pharmaceuticals.
Get Sample Page Now: https://www.credenceresearch.com/sample-request/59602
Report Scope by Segments
Anticoagulant reversal drugs market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on drug class and geography.
By Drug Class (2016–2026; US$ Mn)
- Prothrombin Complex Concentrates (PCC)
- Vitamin K
- Tranexmic Acid
- Pipeline Analysis
- Phase III Drugs (Forecast till 2026)
- Phase I and II Drugs (Tabular Representation)
Geography Segment (2016–2026; US$ Mn)
- North America
- Rest of Europe
- Asia Pacific (APAC)
- Rest of APAC
- Latin America (LATAM)
- Rest of Latin America
- Middle East and Africa (MEA)
- Rest of Middle East and Africa
Market is studied in order to understand the current dynamics and future trends in the global anticoagulant reversal drugs market. The study includes market size and forecast for all considered segments presented in the report for the period from 2016 to 2026, along with respective compound annual growth rate (CAGRs) for the forecast period from 2018 to 2026, considering 2017 as the base year. The key players currently engaged in anticoagulant reversal drugs market include Boehringer Ingelheim GmbH, Fresenius Kabi AG, Bausch Health Companies, Inc., Pfizer, Inc., CSL Behring Limited, Octapharma AG, Portola Pharmaceuticals, Inc., Perosphere Pharmaceuticals, Inc. and Ferring Pharmaceuticals.
Key questions answered in this report
- How the global anticoagulant reversal drugs market will perform during the forecast period from 2018 to 2026?
- What are the latest trends in the anticoagulant reversal drugs market and valuable opportunities for key players?
- Who are the leading players in the global anticoagulant reversal drugs market?
- Which is the leading and fastest region in the global anticoagulant reversal drugs market?
- What are drivers and restrains governing the global anticoagulant reversal drugs market?
- What is the pipeline of anticoagulant reversal drugs market?
Inquiry Before Buying: https://www.credenceresearch.com/inquiry-before-buying/59602